The affinity maturation, characteristics and application of HIV-1 broadly neutralizing antibodies.
10.3760/cma.j.cn112150-20210623-00606
- Author:
Xin Rui WAN
1
;
Ming SUN
2
;
Ya LI
1
Author Information
1. Department of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University, Yunnan Key Laboratory of Laboratory Medicine, Yunnan Innovation Team of Diagnosis, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.
2. Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming 650118, China.
- Publication Type:Journal Article
- MeSH:
Antibodies, Neutralizing;
Broadly Neutralizing Antibodies;
HIV Antibodies;
HIV Infections;
HIV-1;
Humans
- From:
Chinese Journal of Preventive Medicine
2022;56(2):225-232
- CountryChina
- Language:Chinese
-
Abstract:
Hundreds of broadly neutralizing antibodies(bNAbs) were successfully isolated from long-term nonprogression(LTNP) of human immunodeficiency virus type 1(HIV-1) infected individuals. Some bNAbs were illustrated could reduce the viral load and the risk of HIV-1 infection. Today, HIV-1 bNAbs are at the center of vaccine development and passive immunization treatment. Usually, the activity of neutralizing antibodies depends on the epitope. The affinity of neutralizing antibodies also plays a vital role in its inhibitory effect. Multiple affinity maturation in vivo actually provides the broad and potent neutralizing activity of HIV-1 bNAbs. When high affinity HIV-1 bNAbs applied in clinic, it can help immune system to remove virus with lower dosage and fewer side effect. While affinity maturation, HIV-1 bNAbs shows unique characteristics, such as extensive of somatic hypermutation(SHM), in-frame insertion and deletion and long CDR 3 region of heavy chain. The key points in the progress that HIV-1 bNAbs affinity maturation will help us understand the relationship between antibodies neutralizing capability and its characteristics.It also potentially provide a reference to design effective HIV-1 immunogen.
